Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)

Market Cap	3.97B +36.6%
Revenue (ttm)	1.76B -9.5%
Net Income	60.00M +18.7%
EPS	0.11 +19.5%
Shares Out	552.92M
PE Ratio	66.18
Forward PE	n/a
Dividend	0.01 (0.19%)
Ex-Dividend Date	Jan 9, 2026

Volume	20,770,410
Average Volume	24,696,078
Open	7.30
Previous Close	7.29
Day's Range	7.05 - 7.31
52-Week Range	4.95 - 9.44
Beta	0.79
RSI	49.90
Earnings Date	Apr 15, 2026

About SHA:600222

Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, pediatric Qingrezhike oral liquid, Huoxiangzhengqi mixture, Danshen and Wuzi Yanzong oral liquid, Shengmaiyin, pediatric compound chicken gizzard chewable tablets, Huperzine A tablets, compound Yimu oral liquid. The company serves hospitals, primary medical institutions, and retail terminals. Henan T...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 2,214
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600222

Financial Performance

In 2025, SHA:600222's revenue was 1.76 billion, a decrease of -9.46% compared to the previous year's 1.94 billion. Earnings were 60.00 million, an increase of 18.74%.